Correction to: Preoperative urine nitrite versus urine culture for predicting postoperative fever following flexible ure

  • PDF / 363,841 Bytes
  • 2 Pages / 595.276 x 790.866 pts Page_size
  • 81 Downloads / 188 Views

DOWNLOAD

REPORT


CORRECTION

Correction to: Preoperative urine nitrite versus urine culture for predicting postoperative fever following flexible ureteroscopic lithotripsy: a propensity score matching analysis Yu‑cheng Ma1 · Zhong‑Yu Jian1 · Hong Li1 · Kun‑Jie Wang1 

© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Correction to: World Journal of Urology https​://doi.org/10.1007/s0034​5-020-03240​-w

Table 3 shows the comparisons of baseline characteristics after applying PSM followed by IPTW two procedures. But, some columns of Table 3 were mislabeled in the original publication of the article. The corrected Table 3 now reports the comparisons of baseline characteristics after conducting PSM as well as those after further performing IPTW.

The original article can be found online at https​://doi.org/10.1007/ s0034​5-020-03240​-w. * Kun‑Jie Wang [email protected] 1



Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu 610041, Sichuan, People’s Republic of China

13

Vol.:(0123456789)



World Journal of Urology

Table 3  Comparison of baseline characteristics between 2 groups after PS-matching and IPTW analysis Variables

1:4 PSM analysis None-POF group

Total fURS cases, n (%) Gender Female, n (%)

96 52 (54.2)

IPTW analysis POF group 24 11 (45.8)

P

Standardized None-POF group difference

/

/

0.615

0.167

POF group

31.44

31

15.9 (50.6)

15(48.4)

P

Standardized difference

/

/

0.822

0.044

Age (year), mean (SD)

53.45 (12.59)

50.33 (13.82)

0.290

0.236

50.60 (12.35)

50.55 (12.74)

0.984

0.004

BMI, mean (SD)

24.16 (2.88)

23.76 (2.89)

0.540

0.140

24.24 (3.03)

24.18 (2.79)

0.907

0.022

Diabetes (YES), n (%)

9 (9.4)

2 (8.3)

1.000

0.037

2.0 (6.3)

2 (6.5)

0.716

0.183

Charlson comorbidity index, n (%)  0

77 (80.2)

20 (83.3)

25.4 (80.9)

25 (80.6)

 1

17 (17.7)

3 (12.5)

5.1 (16.1)

5 (16.1)

 2 PCNL within 12 month, n (%)

2 (2.1)

1 (4.2)

3 (3.1)

1 (4.2)

1.000

0.056

0.9 (3.0)

1 (3.2)

1.8 (5.7)

2 (6.5)

0.969

0.007

0.998

0.012

0.868

0.032

SWL within 12 month, n (%)

6 (6.2)

2 (8.3)

1.000

0.080

2.1 (6.7)

2 (6.5)

0.958

0.011

URS within 12 month, n (%)

5 (5.2)

2 (8.3)

0.922

0.125

2.1 (6.6)

2 (6.5)

0.971

0.007

1.73 (0.73, 2.90)

1.88 (0.98, 3.05)

0.891

0.033

1.86 (0.88, 3.19)

1.89 (1.08, 3.12)

0.820

0.040

0.412

0.506

1.000

0.056

6 (6.2)

1 (4.2)

1.0 (3.3)

1 (3.2)

Stone burden ­(cm3), median (IQR) Stone location, n (%) Upper calyx Middle calyx

8 (8.3)

2 (8.3)

2.0 (6.2)

2 (6.5)

Lower calyx

12 (12.5)

3 (12.5)

3.3 (10.4)

3 (9.7)

Renal pelvis

20 (20.8)

2 (8.3)

4.6 (14.7)

5 (16.1)

Ureteropelvic Joint

1 (1.0)

2 (8.3)

2.3 (7.2)

2 (6.5)

Ureter

6 (6.2)

2 (8.3)

2.2 (6.9)

2 (6.5)

Multiple locations

43 (44.8)

12 (50.0)

16.1 (51.3)

16 (51.6)

Hydronephrosis (YES), n (%) 64 (66.7)

15 (62.5)

0.885

0.087

18.1 (57.5)

18 (58.1)

0.952

0.012

Urethal stent indewelling (days), median (IQR)

20 (14, 30)

14 (14, 30)

0.964

0.009

20 (14, 30)

20